The National Institute of Allergy and Infectious Diseases (NIAID) awarded Nanopath Inc., a woman-owned small business, a $996,726 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a 15-minute point-of-care molecular diagnostic test for urinary tract infections (UTIs). The test will be capable of identifying UTI-causing pathogens and key genetic markers of antibiotic resistance directly from patient urine samples, without the need for traditional culture or nucleic acid amplification methods. The project aims to expand the detection panel to cover over 95% of UTI-causing organisms and optimize the assay cartridge design. Successful commercialization of this technology will enable rapid point-of-care characterization of UTIs, expedite appropriate antibiotic treatment, and help combat the growing problem of antibiotic resistance.
Generated 2/25/25, 4:02 AM